Japan Lifeline (7575) investor relations material

Executive summary

• Achieved record Q1 FY2027 net sales of ¥15,904 million, up 8.8% year-over-year, driven by strong growth across core and new therapeutic areas.

• Net income rose 0.3% to ¥2,309 million, aided by the reversal of an allowance for doubtful accounts and foreign exchange gains.

• Operating profit declined 9.4% to ¥2,965 million due to increased R&D and personnel investments, resulting in an 18.6% margin.

• All major business areas except Cardiac Rhythm Management posted sales growth, with Neurovascular and Gastrointestinal segments achieving double-digit increases.

• FY2027 guidance for sales and profit remains unchanged; dividend forecast revised upward to include a commemorative payout.

Financial highlights

• Gross margin contracted by 230 basis points to 57.7% year-over-year, despite a 160 basis point improvement in proprietary sales mix.

• SG&A expenses increased 12.9% to ¥6,200 million, reflecting higher personnel and R&D costs.

• Proprietary product sales mix improved to 57.2% (up 160 bps YoY); international sales mix rose to 2.7%.

• Basic and diluted EPS was ¥32.93, up ¥0.08 YoY.

• Achieved 25.2% of annual net sales, 27.7% of operating profit, and 28.9% of net income targets in Q1, pacing ahead of internal models.

Outlook and guidance

• Full-year forecast reaffirmed: Net sales ¥63,200 million (+6.8% YoY), operating profit ¥10,700 million (−15.1% YoY), net income ¥8,000 million (−14.4% YoY), EPS ¥114.02.

• Dividend forecast revised upward to ¥81 per share, including a ¥25 interim commemorative dividend for the 25th manufacturing anniversary.

• Net sales, operating profit, and net income are all tracking ahead of pace to meet full-year FY2027 guidance.

• Business outlook expects continued growth in EP/Ablation, Cardiovascular, Neurovascular, and Gastrointestinal segments, with some headwinds in Cardiac Rhythm Management due to competitor products.